Psychedelics – Products

Awakn Life Sciences Corp. announced today the completion of the world's first ketamine treatment study for behavioral addictions.

Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury.

Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).

Awakn Life Sciences Corp. has announced that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.

Origin Therapeutics Holdings Inc. an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.

Learn about the focus of current psychedelic research efforts and where the most promising progress is being made in this exciting area of drug discovery and development.

Dimensions Health Centres, a psychedelic treatment company, have officially announced the company formation and subsequent closure of an initial, oversubscribed round of funding.

Havn Life Sciences Inc. a biotechnology company, announced it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project.

Cybin Inc. today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc.

Havn Life is a biotechnology company aimed at improving cognitive performance through the standardized extraction of psychoactive compounds and the development of natural health care products from novel compounds.